{"entity":{"id":"nct04810078","kind":"trial","name":"A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advance","aka":[],"tldr":"A phase 3 trial of Nivolumab in renal cell carcinoma, run by Bristol-Myers Squibb, active and no longer recruiting.","summary":"A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread is a phase 3 interventional study registered as NCT04810078 by Bristol-Myers Squibb, with 681 participants enrolled, started 2021-05-21 and due to reach its primary completion in 2025-07-29. Interventions recorded: Nivolumab and rHuPH20, Nivolumab. Conditions listed: Clear Cell Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04810078","url":"https://clinicaltrials.gov/study/NCT04810078"}],"tags":["ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04810078","phase":"3","setting":"A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Have Received Prior Systemic Therapy","sponsor":"Bristol-Myers Squibb","enrolled":681,"outcomes":[]},"route":"/trials/nct04810078/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}